The possible mechanism by which BI synergistically enhances the anti-tumor efficacy mediated by 5-FU was further investigated in a pathway of glycogen synthase kinase-3β (GSK-3β), which may be a target of BI to regulate the anti-tumor effects of 5-FU. The gene discussed is CACNA1A; the disease is neoplasm.